伤寒结合疫苗的现场有效性：2018年孟买新市镇儿科伤寒结合疫苗接种活动

Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign.

作者信息

Date Kashmira, LeBoa Christopher, Hoffman Seth A, Haldar Pradeep, Harvey Pauline, An Qian, Zhang Chenhua, Yewale Vijay N, Daruwalla Savita, Dharmapalan Dhanya, Gavhane Jeetendra, Joshi Shrikrishna, Rai Rajesh, Rathod Varsha, Shetty Keertana, Warrier Divyalatha S, Yadav Shalini, Shimpi Rahul, Jayaprasad Niniya, Horng Lily, Fagerli Kirsten, Borhade Priyanka, Chakraborty Debjit, Katkar Arun, Kunwar Abhishek, Andrews Jason R, Bahl Sunil, Bhatnagar Pankaj, Dutta Shanta, Luby Stephen P

机构信息

Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.

Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.

出版信息

Am J Trop Med Hyg. 2024 Aug 13;111(4):848-852. doi: 10.4269/ajtmh.24-0181. Print 2024 Oct 2.

DOI:10.4269/ajtmh.24-0181

PMID:39137766

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11448546/

Abstract

Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05-0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0-95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.

摘要

Typbar-TCV®是一种伤寒结合疫苗（TCV），于2017年获得世界卫生组织的预认证。我们在2018年9月至2020年7月期间，对印度新孟买针对9个月至14岁儿童的大规模疫苗接种计划中该疫苗的有效性进行了评估。我们将来自六个临床地点的实验室确诊伤寒病例与年龄匹配的社区对照进行了比较。在38例病例中，有3例（8.6%）通过该活动接种了TCV，而在140名对照中有53例（37%）接种了TCV。接种疫苗儿童中伤寒热的调整后比值比为0.16（95%置信区间：0.05 - 0.55），相当于疫苗有效性为83.7%（95%置信区间：45.0 - 95.3）。在这次大规模公共部门疫苗引入中，Typbar-TCV的疫苗有效性与之前的随机对照试验相似，这让政策制定者放心，即TCV在大规模实施中有效性良好。